ZIM Laboratories Limited

NSE ZIMLAB.NS

ZIM Laboratories Limited Return on Assets (ROA) for the year ending March 31, 2024: 3.86%

ZIM Laboratories Limited Return on Assets (ROA) is 3.86% for the year ending March 31, 2024, a -46.04% change year over year. Return on assets measures profitability against assets; higher ROA indicates efficient asset use and profitability.

ZIM Laboratories Limited Return on Assets (ROA) for the year ending March 31, 2023 was 7.15%, a 67.95% change year over year.
ZIM Laboratories Limited Return on Assets (ROA) for the year ending March 31, 2022 was 4.26%, a 89.04% change year over year.
ZIM Laboratories Limited Return on Assets (ROA) for the year ending March 31, 2021 was 2.25%, a 122.33% change year over year.
ZIM Laboratories Limited Return on Assets (ROA) for the year ending March 31, 2020 was 1.01%, a -78.30% change year over year.

Key data

Date	Return on Assets (ROA)	Return on Equity (ROE)	Return on Capital Employed (ROCE)	Interest Coverage Ratio

NSE: ZIMLAB.NS

ZIM Laboratories Limited

CEO	Dr. Chandrashekhar Mainde
IPO Date	Nov. 25, 2022
Location	India
Headquarters	Sadoday Gyan
Employees	556
Sector	Healthcare
Industries Pharmaceuticals Clinical Trials Drugstores & Retail Pharmacies Fertilizers

Description

ZIM Laboratories Limited develops, manufactures, and supplies pharmaceutical formulation and pre formulation ingredients in India and internationally. The company provides technology-based drug delivery solutions and non-infringing proprietary manufacturing processes for generic pharmaceutical products in semi-finished and finished categories/formulations, such as granules, pellets, taste masked powders, suspensions, tablets, capsules, and oral thin films. It serves therapeutic areas, such as urology, gastroenterology, cardiology, and anticoagulants, as well as antibiotics and anti-infectives, NSAIDs/pain analgesics, and vitamins and supplements. ZIM Laboratories Limited was incorporated in 1984 and is based in Nagpur, India.

Key trends

Past 5 years